NEW YORK, Nov. 10 /PRNewswire/ -- The Prostate Cancer Foundation today announced the recipients of the Foundation’s 2003 Donald S. Coffey-CaP CURE Physician-Scientist Award during its 10th annual Scientific Retreat in New York City. The Donald Coffey-CaP CURE Physician-Scientist Awards are designed to honor Dr. Coffey’s decades-long commitment to prostate cancer research and his recognition of the important role physician-scientists play in research. The four awardees were chosen for their compassionate and expert care of prostate cancer patients and laboratory research that moved the field forward in a significant way. The PCF recognizes the role that Dr. Coffey and the four awardees have played in improving the lives of all men affected by prostate cancer.
This year’s award recipients are: ... Anthony V. D’Amico, M.D., Ph.D., Chief, Genitourinary Radiation Oncology, Brigham & Women’s Hospital and Dana-Farber Cancer Institute, and Associate Professor of Radiation Oncology, Harvard Medical School. Dr. D’Amico has performed research to assess the value of PSA (prostate specific antigen) as a surrogate for prostate cancer specific survival. ... Massimo F. Loda, M.D., Associate Professor of Pathology, Harvard Medical School, Department of Medical Oncology, Dana-Farber Cancer Institute. Dr. Loda has pioneered studies of the molecular changes in human prostate tissues associated with the progression of prostate cancer. ... Joel Nelson, M.D., Frederic N. Schwentker Professor and chairman of the Department of Urology at the University of Pittsburgh School of Medicine, and co-director of the University of Pittsburgh Cancer Institute’s Comprehensive Prostate and Urologic Cancer Center. Dr. Nelson validated the role of a molecular pathway involved with prostate cancer progression in bone. ... Jonathan Simons, M.D., Director, Winship Cancer Institute, and Professor and Chair of Hematology and Oncology, Robert W. Woodruff Health Sciences Center, Emory University School of Medicine. Dr. Simons has introduced novel prostate cancer vaccines for the treatment of recurrent prostate cancer.
Leslie D. Michelson, the Prostate Cancer Foundation’s vice chairman and chief executive officer, commented, “Each year, the Foundation’s Retreat gathers the country’s leading researchers developing new therapies designed to treat and, some day, cure prostate cancer. During this forum, we believe it is important to recognize physicians who have contributed greatly to advancing this cause and addressing a disease that affects millions of American families.”
The Prostate Cancer Foundation Scientific Retreat has become the most important international scientific conference for prostate cancer. The conference gathers the most highly-regarded scientific thought leaders in prostate cancer research for three days of scientific presentations, poster sessions and intense dialogue regarding clinical data, new discoveries, emerging treatment strategies and policies to accelerate drug discovery and development.
Sponsors of the Scientific Retreat include Aventis, Abbott Laboratories, Bristol-Myers Squibb Company and AstraZeneca.
About the Prostate Cancer Foundation
The Prostate Cancer Foundation (formerly CaP CURE) is dedicated to finding better treatments and a cure for prostate cancer. Prostate cancer is the most common non-skin cancer in America, striking 220,000 men each year. One new case every 2 1/2 minutes. Since inception in 1993, the Prostate Cancer Foundation (PCF) has become the world’s largest philanthropic source of support for prostate cancer research. The PCF has raised approximately $200 million and funded more than 1,100 critical research projects in 100 research centers around the world. The PCF invests 78 cents of every dollar raised on medical and scientific research, more than three times the average amount spent by the other major health-care philanthropies. Further information is available at: http://www.prostatecancerfoundation.org/
CONTACT: Erika Beck, the Prostate Cancer Foundation, +310-570-4705, or Justin Jackson, Burns McClellan for the Prostate Cancer Foundation, +1-212-213-0006
The Prostate Cancer Foundation
CONTACT: Erika Beck of the Prostate Cancer Foundation, +310-570-4705; orJustin Jackson of Burns McClellan, +1-212-213-0006, for the Prostate CancerFoundation
Web site: http://www.prostatecancerfoundation.org/
